Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies

From Concept to Practice

Inbunden, Engelska, 2024

AvOwen A. O'Connor,Stephen M. Ansell,John G. Gribben

2 769 kr

Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biologyFocuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanismsCovers FDA-approved drugs and their indications, as well as drugs currently in developmentProvides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacyIncludes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.

Produktinformation

Utgivningsdatum2024-03-21
Mått223 x 282 x 32 mm
Vikt1 559 g
FormatInbunden
SpråkEngelska
SeriePrecision Cancer Therapies
Antal sidor496
FörlagJohn Wiley and Sons Ltd
ISBN9781119824541

Tillhör följande kategorier

Onkologi inom Medicin

OWEN A. O’CONNOR, MD, PhD, American Cancer Society Research Professor; Professor of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA. STEPHEN M. ANSELL, MD, PhD, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. JOHN G. GRIBBEN, MD, DSc, Hamilton-Fairley Chair of Medical Oncology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK.

List of Contributors xixVolume Foreword xxivVolume Preface xxviSeries Preface xxviiiSection I Historical Perspective 11 The Distinguished History of Immunotherapy Development in Cancer 3Stephen M. AnsellSection II Targeting Cell Surface Receptors 92 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage 11George J. Weiner3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 22Jennifer K. Lue and Bruce D. Cheson4 Pharmacology to Practice: Targeting CD19 and 22 40Nilanjan Ghosh and Sonali M. Smith5 Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4 52Michael WangSection III Antibody Drug Conjugates (ADC) 736 Principles of Antibody Drug Development 75Eric L. Sievers7 Targeting CD30 in Lymphoid Neoplasms 87Barbara Pro8 Targeting CD79b in B-cell Malignancies 100Colette Owens and Gilles Salles9 Radioimmunotherapy: Is There Any Future Role? 108Alessandro Broccoli and Pier Luigi ZinzaniSection IV Targeting Immune Checkpoint 12310 The Biology of Immune Checkpoint Blockade 125Timothy N. Bullock11 Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1/PDL-1 and CTLA-4 139Marc-Anthony Rodriguez, Ryan Bucktrout, Andrea Orlando, Inna Serganova, and Roberta Zappasodi12 Other Immune Checkpoint Targets of Interest 156Clifford M. Csizmar and Stephen M. Ansell13 Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas 190John M. TimmermanSection V Targeting Macrophages and SIRP-α – Disrupting the "Do Not Eat Me" 20914 The Role of CD47 in Lymphoma Biology and Strategies for Therapeutic Targeting 211Mithunah Krishnamoorthy, Robert A. Uger, and Mark Wong15 Single Agent and Rational Combination Experiences with Anti-CD47 Targeted Drugs 225Nadia Khan, Swathi Namburi, and Krish PatelSection VI EBV Directed Immunotherapies 23316 Understanding the Role of EBV Infection in Lymphomagenesis 235Hiroshi Kimura and Takayuki Murata17 Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies 246Jason Yongsheng CHAN, Seok Jin Kim, Soon Thye LIM, Choon Kiat ONG, and Won Seog KimSection VII Exploiting Tumor Associated Antigens with Autologous T-Cells 25718 The Scientific Rationale for Targeting Tumor-Associated Antigens 259Jean-Sébastien Delisle and Marie-France Aubin19 Clinical Experiences with TAA-T in Lymphoid Malignancies 276Keri Toner, Hannah Kinoshita, and Catherine M. BollardSection VIII Chimeric Antigen Receptor T-Cells (CAR-T) 28920 The Science of CAR-T Cell Technology 291Richard C. Godby, Allison M. Bock, Saad S. Kenderian, and Yi Lin21 The Spectrum of CAR T Assets in Development: Similarities and Differences 304J. Erika Haydu and Jeremy S. Abramson22 Clinical Experience with CAR-T Cells for Treatment of B-cell Lymphomas 318Stephen J. Schuster and John G. Gribben23 "Off the Shelf" CAR-T/NK Cells 341Nancy D. Marin, Alice Zhou, Miriam T. Jacobs, and Todd A. Fehniger24 Programming Myeloid Cells with Chimeric Antigen Receptor Myeloid-Based Therapies 360Miriam Barnett, Michele Gerber, Siddartha Mukherjee, and Daniel GettsSection IX Miscellaneous Topics in Immunotherapy 37325 Mechanistic Basis and Role of Immunomodulatory Drugs 375John G. Gribben26 Analytical Tools to Quantitate Immune Mediated Effects: What Should We Measure and How? 384Kevin D. Pavelko and Jose C. Villasboas27 The Role of the Microbiome in Immune Response 397Máire A. Conrad, Kathleen E. Sullivan, and Judith Kelsen28 Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response 406Enrica Marchi, Ipsita Pal, John Sanil Manvalan, Kallesh Danappa Jayappa, and Owen A. O'Connor29 Tailoring Specific Radiographic Response Criteria for Immunologic Therapies in Lymphoma 429Bruce D. ChesonConclusions 433Must Reads 433References 433Index 436